-
$700 million antihypertensive drug!
Time of Update: 2021-08-29
Data source: Mi Neiwang database, NMPA Medical Network News, August 12 Recently, Yangtze River Haini Pharmaceuticals entered the administrative approval stage with imitation of azilsartan tablets submitted for production in Category 3, and is expected to be approved and deemed to have been reviewed .
-
1 billion cardiovascular injections welcome the first review
Time of Update: 2021-08-29
A few days ago, the official website of the State Food and Drug Administration showed that Broad Pharmaceutical (China)'s norepinephrine bitartrate injection was approved as a supplementary application, making it the first company to have reviewed the product .
-
Reverse transformation from unmet medical needs to new drug design: oligometastatic tumors
Time of Update: 2021-08-28
With the deepening of our understanding of the clinical characteristics of tumors and the accumulation of clinical experience, a type of so-called oligometastatic tumors between early local tumors and multi-point metastatic advanced tumors is becoming a new subtype or new disease state recognized by clinicians .
-
U.S. FDA approves Eglin's EG-007 to enter Phase III pivotal clinical trial
Time of Update: 2021-08-28
S. Food and Drug Administration (FDA) to carry out combined use with targeted drugs and anti-PD-1 antibody drugs A pivotal phase III clinical trial for the treatment of advanced endometrial cancer .
-
Yuandong's first review of 700 million varieties
Time of Update: 2021-08-27
Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation .
-
Shaanxi Buchang High-tech Pharmaceutical wins over $7 billion in star drug
Time of Update: 2021-08-27
A batch of antithrombotic drugs, the total sales of this product in China's public medical institutions and Chinese urban physical pharmacies in 2020 will be close to 4 billion yuan .
-
Colun and Shiyao, the first weekly hypoglycemic drugs to take the lead in imitation
Time of Update: 2021-08-27
On August 5, 2021, the official website of the State Food and Drug Administration showed that Tanabe Mitsubishi Pharmaceutical's titagliptin hydrobromide tablets were approved for import .
-
Servier Tibsovo combined with Azacitidine in the treatment of patients with AML reached the primary end point in Phase 3 clinical trials
Time of Update: 2021-08-15
A few days ago, Servier announced Tibsovo (ivosidenib) combined with Azacitidine chemotherapy for the third global phase 3 double-blind placebo-controlled AGILE trial of previously untreated IDH1-mutated adult acute myeloid leukemia (AML) patients The primary endpoint of event-free survival (EFS) was reached .
-
Behind over 1 billion exposures, how does Douyin e-commerce build a "garden" of dreams for hundreds of millions of fans?
Time of Update: 2021-08-15
At the time of the rebirth, an industry break is happening: backed by high-quality talent content, massive loyal users, the increasingly vigorous system of Douyin e-commerce, green plants, gardening and vertical businesses, etc.
-
PML risk reduced by 88%!
Time of Update: 2021-08-15
On August 2, Biogen announced the results of the Phase 3b NOVA study, which is a 2-year prospective, randomized, interventional, controlled, open-label study, receiving Tysabri (natalizumab) once every 4 weeks (Q4W) Intravenous infusion (IV) dosing regimen is carried out in patients with relapsing-remitting multiple sclerosis (RRMS) whose disease has been stable for at least one year.
-
ADC: A "biological missile" for cancer treatment?
Time of Update: 2021-08-15
An ideal ADC can accurately identify tumor cells without disturbing normal cells; after entering the cell, it releases enough cytotoxic drugs to kill tumor cells .
Most clinical trials and approved drugs target lymphoma and leukemia, and among solid tumors, only breast cancer has drugs on the market .
-
Novo Nordisk's long-acting treatment for hemophilia A starts phase 3 clinical trials in China
Time of Update: 2021-08-15
On July 28, China’s drug clinical trial registration and information disclosure platform showed that Novo Nordisk has launched the new drug turoctocog alfa pegol (N8-GP) in China for the treatment of
-
Sichuan pharmaceutical companies will win the TOP1 anti-dementia drug retail market to grow rapidly
Time of Update: 2021-08-15
Data source: CDE official website, Minet database Pharmaceutical Network News, August 5 Recently, Sichuan Meidakang Pharmaceutical's 4 generic listing applications for Memantine Hydrochloride Tablets have entered the approval status .
-
137 pharmaceutical companies released their transcripts for the first half of the year!
Time of Update: 2021-08-15
In the first half of the year, nearly 70% reported good news: 9 net profits exceeded 1 billion, and 7 interim reports from Zuoli and Jianmin were published first At present, 137 pharmaceutical companies in A-shares disclosed their performance in the first half of 2021, and nearly 70% reported good news .
-
FDA approves new SLE drug
Time of Update: 2021-08-15
[News event]: Yesterday AstraZeneca announced that the FDA approved its type I IFN (IFNI) receptor antibody Saphnelo (generic name anifrolumab-fnia) for the treatment of patients with moderate to severe systemic lupus erythematosus (SLE) who are using standard therapies Treatment .
-
12 million yuan!
Time of Update: 2021-08-15
Medical Network, August 4 News On August 2, Fangsheng Pharmaceutical issued an announcement stating that it has decided to transfer the ownership of two drug varieties, "Xiaoer Compound Sivia Iron Powder" and "Xiaoer Siwei Portuguese Calcium Granules" for 12 million yuan .
-
Successfully isolated the delta mutant strain Kangtai Biology rose sharply in the early trading
Time of Update: 2021-08-15
In the follow-up, strain evaluation will be carried out in strict accordance with the quality requirements of human vaccines, and vaccine strains will be screened to prepare for the production of inactivated new crown vaccines against delta mutant strains .
-
Nanjing Chia Tai Tianqing is showing off! Two-dose form of siege Bayer's "super antibiotics"
Time of Update: 2021-08-15
Data source: CDE official website, Minet database Medical Network, August 5 News On August 3, Nanjing Chia Tai Tianqing submitted four types of generic listings of Tedizolamide Phosphate Tablets, and the application was undertaken by CDE .
-
The sales of new dosage forms of expectorants under a Shandong pharmaceutical company exceed 4 billion
Time of Update: 2021-08-15
Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms .
-
Regeneron/Sanofi Libtayo+ chemotherapy first-line treatment of advanced lung cancer phase 3 clinical trial success
Time of Update: 2021-08-14
On August 5, Sanofi and Regeneron announced that the key phase 3 study evaluating PD-1 tumor immunotherapy Libtayo combined with chemotherapy for the first-line treatment of advanced lung cancer was terminated early due to the very significant efficacy in the initial analysis .
